Therapeutic area intelligence for Proton Pump Inhibitor with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

FDA →

Meitheal →

Shuangcheng →

Recent signals(3)

StrategyJuly 5, 2026

FDA Grants Approval for Pantoprazole Sodium ANDA219973

The FDA has granted approval for ANDA219973, a generic version of Pantoprazole Sodium, submitted by Shuangcheng.

RegulatoryJune 23, 2026

FDA Grants AP Status for Pantoprazole Sodium Supplement by Meitheal

The FDA has granted Abbreviated Approval (AP) status for the Pantoprazole Sodium supplement submitted by Meitheal.

RegulatoryJune 22, 2026

FDA Grants Approval for Rabeprazole Sodium ANDA204237

The FDA has granted approval for ANDA204237, a supplemental application for Rabeprazole Sodium submitted by Rubicon Research.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.